MedTrace Logo

Pharmacokinetic Study of Marine Active in Health Men

NCT00207974 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2005-11-17

No results posted yet for this study

Summary

Hyperuricemia is often associated with metabolic syndrome, which is a known precursor of atherosclerosis. The Yaizu Suisankagaku Industry Company have developed industrial production, named Marine Active. Human clinical trials showed reduction of creatine phosphokinase activity and sero-uric acid. Randomize, double blind clinical trial is entrust to our hospital. This study design is blood sampling from the health men who take 1 gm of marine active to analyse the pharmacokinetics of anserine.

Conditions

  • Hyperuricemia, Anserine, Pharmacokinetic

Interventions

DRUG

Marine active

Sponsors & Collaborators

  • China Medical University Hospital

    lead OTHER

Principal Investigators

  • Kuo-Chin Huang, MD · Chinese-Western Medicine Cooperation, China Medical University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00207974 on ClinicalTrials.gov